PPT-Effect of high-intensity statin therapy on

atherosclerosis in noninfarct related coronary arteries a serial intravascular ultrasonography study IBIS4 Integrated Biomarkers and Imaging Study Lorenz Räber Masanori Taniwaki Serge Zaugg. Louis H. Stein, Jessica Berger, Maryann . Tranquilli. , . John A. . Elefteriades. .. . The Aortic Institute at Yale – New Haven Hospital . Bench top to bedside interaction. . Medial Degeneration . Under-Representation of Women . in Clinical Trials. CVD in Women. Women. ’. s CV Risk is Often Misunderstood or Misdiagnosed. Gender Disparities in Screening, Diagnosis, and Treatment of Dyslipidemia. 2013 ACC/AHA Cholesterol Guidelines. Statin Initiation Recommendations. Multiple Challenges in Statin Selection. Intensity of Statin Therapy. 2013 ACC/AHA Cholesterol Guidelines. Statin Safety Recommendations. DO NOT BURN THE COOKIES. Amy R. Woods, M.D.. a. common goal. a. common goal. “These guidelines are meant to define practices that meet the needs of patients in most circumstances and are not a replacement for clinical judgment. The ultimate decision about care of a particular patient must be made by the healthcare provider and patient in light of the circumstances presented by that patient. As a result, situations might arise in which deviations from these guidelines may be appropriate. These considerations notwithstanding, in caring for most patients, clinicians can employ the recommendations confidently to reduce the risks of atherosclerotic cardiovascular disease (ASCVD) events.”. Purpose. Outline highlights from the 2018 ACC/AHA Guideline on the Management of Blood Cholesterol. Review statin management in high risk patients. 2. ACC/AHA 2018: Overall Approach. Assess risk, determine management group. Beauty is in the Eye of the Beholder. Brian Asbill, MD. Asheville Cardiology Associates. Overview. NHLBI, ACC, AHA expert panel convened 2008. First new guidelines since ATP III guideline update in . Blood . Cholesterol And. Assessment of Cardiovascular Risk. Elena Kuklina, MD, Ph.D.. Senior Service Fellow. State . Grantee . Webinar, . Hypertension, Cholesterol and Sodium Guidelines: Implications for Cardiovascular Health . Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). Debra Griner, MS FNP-C. Mesa Primary Care. Casper, Wyoming. Disclosures. None. Objectives. Identify causes of hyperlipidemia (HLD). Treatment Guidelines. Who should be treated for HLD & Goal. 3. Prevention. /Lipid management in . Diabetes. Dr.Zahra. . davoudi. Endocrinology department of . Loghman. Hakim Hospital, . Shahid. . Beheshti. University of Medical Sciences. A . 65 year-old woman . with medical history of . Which ONE of the following statements regarding the mechanism of action of PCSK9 inhibitors is CORRECT?. a. Reduced hepatic production of LDL-C by inhibition of ATP citrate lyase. b. Increased LDL receptor (LDLR) surface density via increase in LDLR recycling and reduced LDLR degradation. to Reduce Atherosclerotic Cardiovascular . Risk in Adults . 2013 ACC/AHA Guideline on. O. verview. RCTs indicated a constant reduction of ASCVD by . statins. in 1ry & 2ry prevention.. No event reduction. of. Dyslipidemia. Navid Saadat, MD. Associate Professor of Endocrinology. Shahid Beheshti University of Medical Sciences. Rationale for . Treatment. Benefit . of . LDL-C. . reduction in . CVD events. Dr Deep Shah, . Clinical. . Lead UCL Partners. Dominic . Studart. , North Thames GMSA Familial . Hypercholesterolaemia. Project Nurse . Aims. What is FH? . Diagnosing FH. Implementing UCLPartners FH Searches .